PriceTargets.com logo

Sartorius Stedim Biotech - DIM Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€208.20 As of 05/7/2024 01:00 AM ET
▲ +2.2 (1.07%)

This chart shows the closing price for DIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sartorius Stedim Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DIM

Analyst Price Target is €0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a -100.00% upside from the last price of €208.20.

This chart shows the closing price for DIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Sartorius Stedim Biotech. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/7/2023HSBCSet Target€390.00
7/22/2022JPMorgan Chase & Co.Set Target€470.00
7/22/2022Berenberg BankSet Target€464.00
4/22/2022Berenberg BankSet Target€454.00
1/29/2021JPMorgan Chase & Co.Set TargetBuy€400.00
(Data available from 5/8/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/11/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/9/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/8/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sartorius Stedim Biotech logo
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Read More

Today's Range

Now: €208.20
Low: €205.00
High: €208.20

50 Day Range

MA: €246.94
Low: €196.50
High: €280.00

52 Week Range

Now: €208.20

Volume

111,012 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sartorius Stedim Biotech?

The following Wall Street analysts have issued reports on Sartorius Stedim Biotech in the last year:
View the latest analyst ratings for DIM.

What is the current price target for Sartorius Stedim Biotech?

0 Wall Street analysts have set twelve-month price targets for Sartorius Stedim Biotech in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for Sartorius Stedim Biotech in the next year.
View the latest price targets for DIM.

What is the current consensus analyst rating for Sartorius Stedim Biotech?

Sartorius Stedim Biotech currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DIM.

What other companies compete with Sartorius Stedim Biotech?

Other companies that are similar to Sartorius Stedim Biotech include Essilor International Société Anonyme, Fielmann Group, Sartorius Aktiengesellschaft, Fresenius SE & Co. KGaA and Genfit. Learn More about companies similar to Sartorius Stedim Biotech.

How do I contact Sartorius Stedim Biotech's investor relations team?

Sartorius Stedim Biotech's physical mailing address is Zone Industrielle Les Paluds, Avenue de Jouques – CS 91051 Cedex, Aubagne 13781, France. The company's listed phone number is 33 4 42 84 56 00. The official website for Sartorius Stedim Biotech is www.sartorius.com. Learn More about contacing Sartorius Stedim Biotech investor relations.